Research On The Anti-monopoly Regulation Of Drug Excessive Pricing Behavior

At present,the society pays great attention to the problem of drug super high pricing in the field of medicine.If the pharmaceutical enterprises want to carry out the super high monopoly pricing behavior,the premise is that they must have the dominant position in the market.With this advantage,drug dealers sell drugs at a price higher than the normal market standard.The super high price of drugs mainly depends on the unique advantages of drugs and the monopoly position of pharmaceutical enterprises,and is a kind of exploitation to consumers.In the current market environment,how to maintain the normal economic order of the pharmaceutical market,ensure the rights and interests of patients are not infringed,the drug monopoly price can be effectively adjusted,and the emergence of drug price monopoly can be avoided.These are the most urgent objectives of the domestic drug market.This paper starts with the economic theory basis of drug price,which provides theoretical basis for the anti-monopoly regulation of drug super high pricing behavior;then,it analyzes the causes and theories,and what causes and behaviors cause the drug super high pricing line.The specific situation is that,first,in order to obtain excess profits,pharmaceutical enterprises will carry out the high-volume commercial bribery,and the expenditure will be paid by consumers;secondly,the patent protection of the new drugs is too long,which extends the monopoly profit of pharmaceutical enterprises.The law grants patents to pharmaceutical R &D enterprises,which is to ensure the return on investment,but instead become the "evergreen tree" and "Bush" of drug R & D companies.Third,even if the patent expires,pharmaceutical enterprises still want to occupy excess profits,they will sign monopoly agreements to ensure that the price of drugs does not reduce prices for a period of time.Therefore,pharmaceutical companies will cover up the delay of generic listing by legal means.Then,the paper discusses the current situation and deficiency of the regulation of super high price anti-monopoly in the pharmaceutical industry in China,and the concludes that the anti-monopoly law of drug super high pricing in China is imperfect,the legislation is not comprehensive and the enforcement is weak;the law and regulations exist competition in regulating the price monopoly in the pharmaceutical industry,the jurisdiction of monopoly price law is obviously more than that of the anti-monopoly law;the consumers’ rights and interests are ignored.Because of the complexity of drug price monopoly,the effect of governance is not ideal.In view of these problems,the author analyzes and studies the regulation of drug super high pricing behavior in the EU and the United States,summarizes the experience and seeks the characteristics of the universality of the system;finally,through the discussion of the four parts of the preceding article,the specific measures to improve the anti-monopoly of drug ultra high pricing behavior are improved.In order to protect the legitimate rights and interests of consumers,improve the anti-monopoly laws and regulations of the pharmaceutical industry,strengthen the independence and responsibility division of the anti-monopoly law enforcement agencies in the pharmaceutical industry,strengthen the cooperation between the anti-monopoly law enforcement agencies and the industry supervision departments,apply the operators’ commitment,etc.,so as to find out the anti-monopoly method of drug price that is suitable for the current situation of China,And gradually establish a comprehensive and effective legal system.